[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586191":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":22,"studyPopulation":11,"armGroups":23,"interventions":39,"overallOfficials":11,"centralContacts":55,"locations":61,"responsibleParty":79,"collaborators":11,"id":81,"slug":11,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":11,"eligibilityCriteria":86,"healthyVolunteers":82,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":11,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":11,"overallStatus":64,"whyStopped":11,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Zhejiang Wenda Pharma Technology LTD.","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Score at Week 16",null,"Screening up to Week 16",{"allocation":14,"interventionModel":15,"interventionModelDescription":11,"primaryPurpose":16,"observationalModel":11,"timePerspective":11,"maskingInfo":17},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":18,"maskingDescription":11,"whoMasked":19},"DOUBLE",[20,21],"PARTICIPANT","INVESTIGATOR","The total duration of this study is up to 24 weeks which includes a screening period of less than or equal to (\\\u003C=) 4 weeks, a 16-week treatment period, and a 4-week safety follow-up period. Aged 18 to 70 years (inclusive) were enrolled in this study. Participants were randomized to receive WD-890 or placebo.",[24,29,32,35],{"label":25,"type":26,"description":11,"interventionNames":27},"Group 1: WD-890 Dose 1 QD and Placebo","EXPERIMENTAL",[28],"Drug: WD-890 tablet",{"label":30,"type":26,"description":11,"interventionNames":31},"Group 2: WD-890 Dose 2 QD and Placebo",[28],{"label":33,"type":26,"description":11,"interventionNames":34},"Group 3: WD-890 Dose 3 QD and Placebo",[28],{"label":36,"type":26,"description":11,"interventionNames":37},"Group 4: Placebo",[38],"Drug: Placebo",[40,45,48,51],{"type":41,"name":42,"description":43,"armGroupLabels":44,"otherNames":11},"DRUG","WD-890 tablet","Participants will receive WD-890 Dose 1 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.",[25],{"type":41,"name":42,"description":46,"armGroupLabels":47,"otherNames":11},"Participants will receive WD-890 Dose 2 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.",[30],{"type":41,"name":42,"description":49,"armGroupLabels":50,"otherNames":11},"Participants will receive WD-890 Dose 3 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.",[33],{"type":41,"name":52,"description":53,"armGroupLabels":54,"otherNames":11},"Placebo","Participants will receive placebo QD from Week 0 through Week 16.",[36],[56],{"name":57,"role":58,"phone":59,"phoneExt":11,"email":60},"Qianjin Lu, doctor","CONTACT","+86 137 8709 7676","qianlu5860@pumcderm.cams.cn",[62],{"facility":63,"status":64,"city":65,"state":66,"zip":67,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":75,"contacts":76},"Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences, Peking Union Medical College","RECRUITING","Nanjing","Jiangsu","210000","China","CN",{"type":71,"coordinates":72},"Point",[73,74],118.77778,32.06167,{"lat":74,"lon":73},[77],{"name":57,"role":58,"phone":78,"phoneExt":11,"email":60},"+86 13787097676",{"type":80,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100586191",false,"NCT06912165","A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis","Inclusion Criteria:\n\n* Male or female participant aged 18 to 70 years(inclusive)at the time of informed consent.\n* Diagnosis of plaque psoriasis for at least 6 months prior to the screening visit.\n\n  ≥10% of BSA involvement at screening visit and randomization;\n* Psoriasis Area and Severity Index (PASI) score ≥12 and static Physician's Global Assessment (sPGA) ≥3 at screening visit and randomization\n\nExclusion Criteria:\n\n* Participant has a nonplaque form of psoriasis (for example, erythrodermic, guttate, inverse, pustular,or drug induced psoriasis.)\n* Has uncontrolled arterial hypertension characterized by a systolic blood pressure (BP) ≥160 mm Hg or diastolic BP ≥100 mm Hg Note: Determined by 2 consecutive elevated readings. If an initial BP reading exceeds this limit, the BP may be repeated once after the subject has rested sitting for ≥10 minutes. If the repeat value is less than the criterion limits, the second value may be accepted\n* Class III or IV congestive heart failure by New York Heart Association Criteria\n* Participant with a history of chronic bacterial infections (e.g., chronic pyelonephritis, chronic bronchiectasis, or chronic osteomyelitis).","ALL","18 Years","70 Years",{"count":91,"type":92},140,"ESTIMATED","INTERVENTIONAL",[95],"PHASE2","Th purpose of the study is to evaluate the dose response of WD-890 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.",[98],"Brief Description of Focus of Study","2025-04-08",{"date":101,"type":102},"2025-04-11","ACTUAL",{"date":104,"type":102},"2024-12-31",{"date":106,"type":92},"2025-11-30",{"name":5,"class":6},1]